EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Low-Dose Salinomycin Targets Multidrug Resistance via P-Glycoprotein and NF-κB in Osteosarcoma Cells

Onarisa Ayu, Muhammad Rusda, Rosita Juwita Sembiring, Iqbal Pahlevi Adeputra Nasution, Ferdiansyah Mahyudin, Mustafa Mahmud Amin, Hotma Partogi Pasaribu, Tina Christina Lumban Tobing

Advance Sustainable Science Engineering and Technology · 25.06.2026 · 8 (3) · 02603028

DOI: 10.26877/asset.v8i3.2447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advance Sustainable Science Engineering and Technology, online erschienen am 25.06.2026. Verfasst von Onarisa Ayu und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy resistance in osteosarcoma remains a major clinical obstacle, largely driven by drug efflux mechanisms mediated by P-glycoprotein (ACBC1/ABCB1) and activation of NF-κB signaling (NFKB1). This study investigated the potential of Salinomycin to modulate these multidrug resistance–associated genes in U2OS osteosarcoma cells and explore its role in overcoming chemoresistance. A true experimental post-test-only control group design was used. U2OS cells were treated with varying concentrations of Salinomycin, doxorubicin, and their combination. Cell viability was assessed using MTT assay, while gene expression of ACBC1 and NFKB1 was quantified using qRT-PCR with SYBR Green chemistry. Relative expression levels were analyzed using the 2−ΔΔCt method normalized to GAPDH. Salinomycin demonstrated dose-dependent cytotoxic effects in the low micromolar range. At lower concentrations, it significantly reduced NFKB1 expression, while also showing a tendency to downregulate ACBC1. However, intermediate concentrations showed variable effects, including a transient increase in NFKB1 expression. The combination treatment with doxorubicin produced only modest and non-significant changes in both resistance-related genes. Overall, low-dose Salinomycin exhibited a more consistent suppressive effect on NF-κB signaling, suggesting a potential role in sensitizing osteosarcoma cells to chemotherapy. In contrast, higher doses primarily enhanced cytotoxicity without clearly improving suppression of resistance markers. This study highlights a novel dual-action, dose-dependent regulatory effect of Salinomycin at the transcriptomic level, targeting both drug efflux (ACBC1/ABCB1) and survival signaling (NF-κB/NFKB1). These findings provide new insight into its potential as an adjunct agent in overcoming multidrug resistance in osteosarcoma and warrant further validation at the protein and functional levels.

Zitieren

APA

Ayu, O., Rusda, M., Sembiring, R. J., Nasution, I. P. A., Mahyudin, F., Amin, M. M., Pasaribu, H. P., & Tobing, T. C. L. (2026). Low-Dose Salinomycin Targets Multidrug Resistance via P-Glycoprotein and NF-κB in Osteosarcoma Cells. Advance Sustainable Science Engineering and Technology, 8(3), 02603028. https://doi.org/10.26877/asset.v8i3.2447

Vancouver

Ayu O, Rusda M, Sembiring RJ, Nasution IPA, Mahyudin F, Amin MM, et al. Low-Dose Salinomycin Targets Multidrug Resistance via P-Glycoprotein and NF-κB in Osteosarcoma Cells. Advance Sustainable Science Engineering and Technology. 2026;8(3):02603028. doi:10.26877/asset.v8i3.2447

BibTeX
@article{Ayu2026,
  author = {Ayu, Onarisa and Rusda, Muhammad and Sembiring, Rosita Juwita and Nasution, Iqbal Pahlevi Adeputra and Mahyudin, Ferdiansyah and Amin, Mustafa Mahmud and Pasaribu, Hotma Partogi and Tobing, Tina Christina Lumban},
  title = {Low-Dose Salinomycin Targets Multidrug Resistance via P-Glycoprotein and NF-κB in Osteosarcoma Cells},
  journal = {Advance Sustainable Science Engineering and Technology},
  year = {2026},
  volume = {8},
  number = {3},
  pages = {02603028},
  doi = {10.26877/asset.v8i3.2447}
}
Kostenlos starten →